Menveo Powder and Solution for Solution for Injection
Product details
Registration number: SIN14083P
Classification: Prescription Only
Active ingredients:
- (MenA Lyo) Meningococcal Group A oligosaccharide conjugated to CRM197 protein
- (MenCWY) Meningococcal Group C oligosaccharide conjugated to CRM197 protein
- (MenCWY) Meningococcal Group W-135 oligosaccharide conjugated to CRM197 protein
- (MenCWY) Meningococcal Group Y oligosaccharide conjugated to CRM197 protein
Strength:
- 10 microgram conjugated to 16.7-33.3 microgram
- 5 microgram conjudated to 7.1-12.5 microgram
- 5 microgram conjugated to 3.3-8.3 microgram
- 5 microgram conjugated to 5.6-10 microgram
Dosage form: INJECTION, POWDER, FOR SOLUTION
Route: INTRAMUSCULAR
Registrant: GLAXOSMITHKLINE PTE LTD
ATC code: J07AH08
HSA approval date: 20 January 2012
Manufacturer(s):
- GSK Vaccines S.r.l. (MenCWY Liquid)
- PATHEON ITALIA S.P.A. (MenA Lyo)
Manufacturing country/countries: ITALY
What are the HSA registration number and classification for Menveo Powder and Solution for Solution for Injection?
According to the HSA dataset updated 7 August 2026:
Registration number: SIN14083P
Classification: Prescription Only
What active ingredients and strength are recorded for Menveo Powder and Solution for Solution for Injection?
According to the HSA dataset updated 7 August 2026:
Active ingredients:
- (MenA Lyo) Meningococcal Group A oligosaccharide conjugated to CRM197 protein
- (MenCWY) Meningococcal Group C oligosaccharide conjugated to CRM197 protein
- (MenCWY) Meningococcal Group W-135 oligosaccharide conjugated to CRM197 protein
- (MenCWY) Meningococcal Group Y oligosaccharide conjugated to CRM197 protein
Strength:
- 10 microgram conjugated to 16.7-33.3 microgram
- 5 microgram conjudated to 7.1-12.5 microgram
- 5 microgram conjugated to 3.3-8.3 microgram
- 5 microgram conjugated to 5.6-10 microgram
Ingredients and strengths are listed separately as recorded by HSA; their positions do not establish a one-to-one match. This is not a dosing instruction.
What dosage form and route are recorded for Menveo Powder and Solution for Solution for Injection?
According to the HSA dataset updated 7 August 2026:
Dosage form: INJECTION, POWDER, FOR SOLUTION
Route: INTRAMUSCULAR
Who is the recorded registrant for Menveo Powder and Solution for Solution for Injection?
According to the HSA dataset updated 7 August 2026:
Registrant: GLAXOSMITHKLINE PTE LTD
Which manufacturers and countries are listed for Menveo Powder and Solution for Solution for Injection?
According to the HSA dataset updated 7 August 2026:
Manufacturer(s):
- GSK Vaccines S.r.l. (MenCWY Liquid)
- PATHEON ITALIA S.P.A. (MenA Lyo)
Manufacturing country/countries: ITALY
Where can I look up Menveo Powder and Solution for Solution for Injection in the HSA register?
Open HSA’s therapeutic product register and search for registration number SIN14083P or the exact product name Menveo Powder and Solution for Solution for Injection. The general register link does not preselect this product.
What are the source dates for this Menveo Powder and Solution for Solution for Injection record?
This record is from HSA’s List of Registered Therapeutic Products on data.gov.sg. Dataset update: 7 August 2026. Retrieval date: 13 November 2026.
The dataset date is a snapshot date, not a separate current-register check for every product. Later direct checks are recorded separately.
Has this Menveo Powder and Solution for Solution for Injection record had a separate HSA register check?
No separate current-register check is recorded for this product. Its presence in the imported dataset does not establish its current registration status.
Search the HSA register using SIN14083P for the latest record.
Sources and dates
HSA dataset: 2026. Updated: 13 November 2026.
Factual product information only; no dosing, treatment or suitability advice.
Updated and reviewed by: Dr Joel Lim MBChB UK (PG Dip Dermatology), Resident Physician.
.png)